1143534-01-3

Basic information

• Product Name: 4-AMINO-4-(4-CHLOROPHENYL)BUTAN-1-OL
• Synonyms: 4-AMINO-4-(4-CHLOROPHENYL)BUTAN-1-OL
• CAS NO: 1143534-01-3
• Molecular Formula: C10H14ClNO
• Molecular Weight: 199.68
• Mol File: 1143534-01-3.mol

Chemical Properties

• CAS DataBase Reference: 4-AMINO-4-(4-CHLOROPHENYL)BUTAN-1-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMINO-4-(4-CHLOROPHENYL)BUTAN-1-OL(1143534-01-3)
• EPA Substance Registry System: 4-AMINO-4-(4-CHLOROPHENYL)BUTAN-1-OL(1143534-01-3)

Safety Data

• Hazardous Substances Data: 1143534-01-3(Hazardous Substances Data)

Upstream product

• 1143533-99-6 4-(4-chlorophenyl)-4-(methoxyimino)butanoic acid 
• 873-77-8 (4-chlorphenyl)magnesium bromide 
• 3984-34-7 4-(4-chlorophenyl)-4-oxobutanoic acid 
• 1143533-97-4 ethyl 4-(4-chlorophenyl)-4-(methoxyimino)butanoate 

Downstream Products

• 1143534-67-1 tert-butyl 1-(4-chlorophenyl)-4-hydroxybutylcarbamate 
• 1143534-97-7 tert-butyl 4-(tert-butoxycarbonylamino)-4-(1-(4-chlorophenyl)-4-hydroxybutylcarbamoyl)piperidine-1-carboxylate 
• 1143534-03-5 tert-butyl 4-(1-(4-chlorophenyl)-4-hydroxybutylcarbamoyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-ylcarbamate 
• 1025437-35-7 1-(4-chlorophenyl)-N⁴,N⁴-dimethylbutane-1,4-diamine 
• 1296851-39-2 1-(4-chlorophenyl)-4-morpholinobutan-1-amine 
• 1296851-46-1 1-(4-chlorophenyl)-4-(piperidin-1-yl)butan-1-amine 
• 1296851-21-2 1-(4-chlorophenyl)-4-(pyrrolidin-1-yl)butan-1-amine 
• 1143532-71-1 4-amino-N-(1-(4-chlorophenyl)-4-(dimethylamino)butyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide 
• 1143533-16-7 4-amino-N-[1-(4-chlorophenyl)-4-pyrrolidin-1-ylbutyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide 
• 1143533-18-9 4-amino-N-[1-(4-chlorophenyl)-4-morpholin-4-ylbutyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide 
• 1143533-20-3 4-amino-N-[1-(4-chlorophenyl)-4-piperidin-1-ylbutyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide 
• 1143532-35-7 4-amino-N-(1-(4-chlorophenyl)-4-hydroxybutyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide 

Relevant articles and documents

Synthesis of 1,4-amino alcohols by Grignard reagent addition to THF and N-tosyliminobenzyliodinane

The synthesis of 1,4-amino alcohols from THF treated with N-tosyliminobenzyliodinane (PhINTs) followed by a Grignard reagent under mild reaction conditions at room temperature is described herein. Various Grignard reagents were shown to be compatible, furnishing the corresponding 4-substituted-N-1,4-tosylamino alcohols in good to excellent yields. A partial or full detosylation of the N-tosyl-1,4-amino alcohol was observed in instances involving a sterically bulky Grignard reagent, leading to the deprotected 1,4-amino alcohol product in moderate to good yields. The synthetic utility of this protocol was demonstrated by the synthesis of a 5-substituted-N-tosyl-1,5-amino alcohol from THP and the conversion of two examples to their corresponding γ-lactam and pyrrolidine adducts.

Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H- pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases

Wide-ranging exploration of analogues of an ATP-competitive pyrrolopyrimidine inhibitor of Akt led to the discovery of clinical candidate AZD5363, which showed increased potency, reduced hERG affinity, and higher selectivity against the closely related AGC kinase ROCK. This compound demonstrated good preclinical drug metabolism and pharmacokinetics (DMPK) properties and, after oral dosing, showed pharmacodynamic knockdown of phosphorylation of Akt and downstream biomarkers in vivo, and inhibition of tumor growth in a breast cancer xenograft model.

PYRROLO [2,3-D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS

The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I)